These findings underscore the potential of the endothelial CTR1-SLC25A3 mitochondrial Cu axis as a therapeutic target for preventing atherosclerosis and other cuproptosis-related diseases, including cardiovascular disorders, cancer, and neurodegenerative diseases. This evidence concerns the gene SLC31A1 and cancer.